Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide in AR-positive Metastatic TNBC
NCT02353988Phase 2Unknown
- Sponsor
- Jinling Hospital
- Start
- Jan 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of bicalutamide in triple-negative breast cancer (TNBC) (2 arms), sponsored by Jinling Hospital. Primary endpoints: Clinical Benefit Rate at 1 year and Progression-free survival at 12 months. Status: unknown.
02
Drugs
bicalutamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02353988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353988.